CLLS
CellectisCLLS
CLLS
About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Employees: 222
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1.17% more ownership
Funds ownership: 17.7% [Q4 2024] → 18.87% (+1.17%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
7% less funds holding
Funds holding: 29 [Q4 2024] → 27 (-2) [Q1 2025]
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
27% less capital invested
Capital invested by funds: $23M [Q4 2024] → $16.9M (-$6.1M) [Q1 2025]
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4
201%
upside
Avg. target
$4
201%
upside
High target
$4
201%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Barclays Gena Wang | 201%upside $4 | Overweight Maintained | 13 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
Positive
Seeking Alpha
1 month ago
Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy
Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies. The financial picture remains strong, bolstered further by a partnership with AstraZeneca. Promised data readouts in late 2025 represent important potential catalysts.
Neutral
GlobeNewsWire
1 month ago
Cellectis Reports Financial Results for the First Quarter 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the first quarter 2025, ending March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
1 month ago
Cellectis to Report First Quarter Financial Results on May 12, 2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market.
Neutral
GlobeNewsWire
1 month ago
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 13-17, 2025 in New Orleans.
Positive
MarketBeat
1 month ago
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
Cellectis S.A. NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology.
Neutral
Seeking Alpha
3 months ago
Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript
Cellectis S.A. (NASDAQ:CLLS ) Q4 2024 Earnings Conference Call March 14, 2025 8:00 AM ET Company Participants Arthur Stril - CFO and Chief Business Officer Andre Choulika - CEO Adrian Kilcoyne - CMO Conference Call Participants Gena Wang - Barclays Jack Allen - Baird Sebastiaan van der Schoot - Kempen Silvan Tuerkcan - Citizens Jack Allen - Baird Hangfei Fu - Jefferies Operator Good day, everyone, and welcome to today's Cellectis Full Year 2024 Earnings Conference Call.
Neutral
GlobeNewsWire
3 months ago
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL.
Neutral
GlobeNewsWire
3 months ago
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market.
Neutral
GlobeNewsWire
3 months ago
Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcases an innovative strategy for T cell engineering that leverages the pro-inflammatory properties of interleukin 2 (IL-2) with the objective to enhance CAR T cell efficacy against solid tumors, at the American Association for Cancer Research – Immuno-oncology (AACR-IO), taking place on February 23-26, 2025 in Los Angeles, CA.
Charts implemented using Lightweight Charts™